Commercial Information Circulars

24-hour hotline : 23 922 922

e-mail address : enquiry@tid.gov.hk

Ref. ： EIC 631/2/5/1

13 June 2017

Dear Sirs,

Commercial Information Circular No. 479/2017

The Mainland of China : Public Consultation on the "Guidance on the Assessment of Generic Drugs for Conformance Assessment on Quality and Efficacy (Type of Drugs Requiring Conformance Assessment) (Consultation Draft)", "Guidance on the Assessment of Generic Drugs for Conformance Assessment on Quality and Efficacy (Type of Drugs Producing Locally and For Sale in Europe, Americas and Japan) (Consultation Draft)" and Related Receipts

The China Food and Drug Administration (CFDA) of the People's Republic of China is seeking comments from the public on the "Guidance on the Assessment of Generic Drugs for Conformance Assessment on Quality and Efficacy (Drugs Requiring Conformance Assessment) (Consultation Draft)", "Guidance on the Assessment of Generic Drugs for Conformance Assessment on Quality and Efficacy (Drugs Producing Locally and For Sale in Europe, Americas and Japan) (Consultation Draft)" and related receipts. Interested parties can submit their comments to the CFDA by email before 9 July 2017. Please refer to the Appendix (pdf format) for the letter inviting public comments (available in Chinese only).

ENQUIRIES

2.If you have any questions on the content of the document mentioned in this circular, please contact the issuing authority of the Mainland of China direct. For other questions on this circular, please contact Mainland Branch (I) (tel: 2398 5444) of the Department.

Yours faithfully,

(Ms Helen CHENG)
for Director-General of Trade and Industry

Note: While every effort is made to ensure the accuracy of the above information, the Department cannot guarantee this to be so and will not be held liable for any reliance placed on the same.